Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIV

Abstract

Background

IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favourable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV–HCV-coinfected patients.

Methods

All HIV–HCV genotype 1 coinfected subjects who received TVR/PR for at least 4 weeks were included from populations prospectively followed in 22 centres throughout Germany, Switzerland and Spain.

Results

Of the 129 subjects included, 38 (29.5%) presented with IL28B genotype CC and 94 (72.9%) were treatment-experienced. A total of 96 (73.8%) patients showed undetectable plasma HCV RNA at treatment week (W)4: 30 (78.9%) of the IL28B-CC carriers and 65 (71.4%) of the non-CC carriers (P=0.377). Among treatment-naive patients, proportions of undetectable HCV RNA among IL28B-CC versus non-CC carriers were 8/9 (88.9%) versus 3/9 (33.3%; P=0.016) and 14/17 (82.4%) versus 11/18 (61.1%; P=0.164) at W2 and W4. The decrease of HCV RNA at W2 and W4 was similar among the IL28B carriers.

Conclusions

IL28B genotype does not predict W4 response to TVR/PR in HIV–HCV-coinfected patients, regardless of their treatment history. However, there is evidence of an impact on response during the first weeks in treatment-naive patients.

References

, Fellay

, Thompson

A.J.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Nature 2009; 461: 399–401.

Tanaka

, Nishida

, Sugiyama

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Nat Genet 2009; 41: 1105–1109.

Suppiah

, Moldovan

, Ahlenstiel

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Nat Genet 2009; 41: 1100–1104.

Pineda

J.A.

, Caruz

, Rivero

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Clin Infect Dis 2010; 51: 788–795.

Jacobson

I.M.

, Catlett

, Marcellin

Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. 46th Annual Meeting of the European Association for the Study of the Liver. 30 March–3 April 2011, Berlin, Germany. Abstract LB1369.

Poordad

, Bronowicki

J.P.

, Gordon

S.C.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Gastroenterology 2012; 143: 608–618.

Bronowicki

J.P.

, Hézode

, Bengtsson

100% SVR in IL28B SNP rs12979860 C/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE-2 trial. 47th Annual Meeting of the European Association for the Study of the Liver. 18–22 April 2012, Barcelona, Spain. Abstract 1094.

Chu

T.W.

, Kulkarni

, Gane

E.J.

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

Gastroenterology 2012; 142: 790–795.

Zeuzem

, Soriano

, Asselah

Faldaprevir and deleobuvir for HCV genotype 1 infection.

N Engl J Med 2013; 369: 630–639.

10.

Rivero-Juárez

, Camacho

, Perez-Camacho

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotypes 1 or 4.

J Antimicrob Chemother 2012; 67: 202–205.

11.

Benito

J.M.

, Sánchez-Parra

, Maida

Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.

Antivir Ther 2013; 18: 709–715.

12.

Sherman

K.E.

, Flamm

S.L.

, Afdhal

N.H.

Response-guided telaprevir combination treatment for hepatitis C virus infection.

N Engl J Med 2011; 365: 1014–1024.

13.

Poordad

, McCone

, Bacon

B.R.

Boceprevir for untreated chronic HCV genotype 1 infection.

N Engl J Med 2011; 364: 1195–1206.

14.

Pol

, Aerssens

, Zeuzem

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

J Hepatol 2013; 58: 883–889.

15.

Dieterich

, Rockstroh

J.K.

, Orkin

Simeprevir plus PegIFN/rivabirin in HCV genotype-1/HIV-1 co-infection (Study C212). 21st Conference on Retroviruses and Opportunistic Infections. 3–6 March 2014, Boston, MA, USA. Abstract 24.

16.

Dieterich

, Tural

, Nelson

Faldaprevir plus pegylated interferon alfa-2a/ribavirin in HIV/HCV coinfection: STARTVerso4. 21st Conference on Retroviruses and Opportunistic Infections. 3–6 March 2014, Boston, MA. Abstract 23.

17.

Nelson

D.R.

, Poordad

, Feld

J.J.

High SVR rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naives and prior relapsers with G1 chronic hepatitis C: CONCISE interim analysis. 48th Annual Meeting of the European Association for the Study of the Liver. 24–28 April 2013, Amsterdam, the Netherlands. Abstract 881.

18.

Kowdley

K.V.

, Lawitz

, Poordad

Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study.

J Hepatol 2013; 58 Suppl 1: S2.

19.

Mandorfer

, Steiner

, Schwabl

Response-guided boceprevir-based triple-therapy in HIV/HCV-coinfected patients: The HIVCOBOC-RGT Study.

J Infect Dis 2015; 211: 729–735.

20.

European AIDS Clinical Society. Clinical management and treatment of chronic HBV and HCV co-infection in HIV-positive persons. (Accessed 20 September 2013.) Available from http://eacsociety.org/Portals/0/Guidelines_Online_131014.pdf.

21.

European Association for the study of the liver (EASL).

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection.

J Hepatol 2011; 55: 245–264.

Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIV–HCV Coinfection